Abstract
Introduction/BackgroundCirculating tumour DNA (ctDNA) is emerging as a potential option to detect disease recurrence in women undergoing follow-up for endometrial cancer (EC). However, ensuring patient acceptability of changing clinical practice...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
